# Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

> **NCT00354601** · PHASE2 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 2 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00354601
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2008-05
- **Final completion:** 2008-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** funding withdrawn
- **Last updated:** 2017-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354601, "Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00354601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*